Induction of p16 during immortalization by HPV 16 and 18 and not during malignant transformation

Y. Nakao, X. Yang, M. Yokoyama, A. Ferenczy, Shou-Ching Tang, M. M. Pater, A. Pater

Research output: Contribution to journalArticle

102 Citations (Scopus)

Abstract

The p16 (MTS1) tumour-suppressor gene is a cyclin-dependent kinase (cdk) inhibitor that decelerates the cell cycle by inactivating the cdks that phosphorylate the retinoblastoma tumour-suppressor gene (Rb) protein (pRb). In cervical cancers, pRb is inactivated by the HPV E7 oncoprotein or by mutations. The hypothesis of earlier reports was that the disruption of the p16/cdk-cyclin/Rb cascade is essential for malignant cervical transformation/carcinogenesis. We previously established in vitro model systems of cervical cancer representing four steps of oncogenic progression initiated by the two most common oncogenic HPVs in ectocervical and endocervical epithelial cells. This report used these systems to investigate the role of p16 in cervical cancers. A dramatic enhancement of the p16 RNA level was observed after immortalization by HPV 16 or 18. Furthermore, the p16 protein was newly observed following immortalization. However, no further changes were found for RNA or protein levels after serum selection or malignant transformation. For three cervical carcinoma cell lines, similar high levels of p16 expression were seen. Point mutations or homozygous deletions of p16 were not observed in the in vitro systems or in clinical specimens. These results suggest that the inactivation of the p16/cdk-cyclin/Rb cascade does not occur during malignant transformation but occurs during the immortalization by HPV in HPV-harbouring premalignant lesions, the in situ equivalent of immortalized cells. Also suggested is that p16 has no role in the specific malignant transformation step from immortal premalignant lesions during the carcinogenesis of HPV-initiated cervical cancers.

Original languageEnglish (US)
Pages (from-to)1410-1416
Number of pages7
JournalBritish Journal of Cancer
Volume75
Issue number10
DOIs
StatePublished - Jan 1 1997

Fingerprint

Human papillomavirus 18
Human papillomavirus 16
Uterine Cervical Neoplasms
Cyclin-Dependent Kinases
Cyclins
Tumor Suppressor Genes
Carcinogenesis
RNA
Retinoblastoma Protein
Proteins
Retinoblastoma
Oncogene Proteins
Point Mutation
Cell Cycle
Epithelial Cells
Carcinoma
Cell Line
Mutation
Serum
In Vitro Techniques

Keywords

  • Cell cycle
  • Cervical cancer
  • Cyclin-dependent kinase
  • Human papillomavirus
  • Immortalization
  • Retinoblastoma tumour suppressor
  • Transformation
  • p16

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Nakao, Y., Yang, X., Yokoyama, M., Ferenczy, A., Tang, S-C., Pater, M. M., & Pater, A. (1997). Induction of p16 during immortalization by HPV 16 and 18 and not during malignant transformation. British Journal of Cancer, 75(10), 1410-1416. https://doi.org/10.1038/bjc.1997.243

Induction of p16 during immortalization by HPV 16 and 18 and not during malignant transformation. / Nakao, Y.; Yang, X.; Yokoyama, M.; Ferenczy, A.; Tang, Shou-Ching; Pater, M. M.; Pater, A.

In: British Journal of Cancer, Vol. 75, No. 10, 01.01.1997, p. 1410-1416.

Research output: Contribution to journalArticle

Nakao, Y, Yang, X, Yokoyama, M, Ferenczy, A, Tang, S-C, Pater, MM & Pater, A 1997, 'Induction of p16 during immortalization by HPV 16 and 18 and not during malignant transformation', British Journal of Cancer, vol. 75, no. 10, pp. 1410-1416. https://doi.org/10.1038/bjc.1997.243
Nakao, Y. ; Yang, X. ; Yokoyama, M. ; Ferenczy, A. ; Tang, Shou-Ching ; Pater, M. M. ; Pater, A. / Induction of p16 during immortalization by HPV 16 and 18 and not during malignant transformation. In: British Journal of Cancer. 1997 ; Vol. 75, No. 10. pp. 1410-1416.
@article{c09f72b9c22d4b3eaeb4483a97998511,
title = "Induction of p16 during immortalization by HPV 16 and 18 and not during malignant transformation",
abstract = "The p16 (MTS1) tumour-suppressor gene is a cyclin-dependent kinase (cdk) inhibitor that decelerates the cell cycle by inactivating the cdks that phosphorylate the retinoblastoma tumour-suppressor gene (Rb) protein (pRb). In cervical cancers, pRb is inactivated by the HPV E7 oncoprotein or by mutations. The hypothesis of earlier reports was that the disruption of the p16/cdk-cyclin/Rb cascade is essential for malignant cervical transformation/carcinogenesis. We previously established in vitro model systems of cervical cancer representing four steps of oncogenic progression initiated by the two most common oncogenic HPVs in ectocervical and endocervical epithelial cells. This report used these systems to investigate the role of p16 in cervical cancers. A dramatic enhancement of the p16 RNA level was observed after immortalization by HPV 16 or 18. Furthermore, the p16 protein was newly observed following immortalization. However, no further changes were found for RNA or protein levels after serum selection or malignant transformation. For three cervical carcinoma cell lines, similar high levels of p16 expression were seen. Point mutations or homozygous deletions of p16 were not observed in the in vitro systems or in clinical specimens. These results suggest that the inactivation of the p16/cdk-cyclin/Rb cascade does not occur during malignant transformation but occurs during the immortalization by HPV in HPV-harbouring premalignant lesions, the in situ equivalent of immortalized cells. Also suggested is that p16 has no role in the specific malignant transformation step from immortal premalignant lesions during the carcinogenesis of HPV-initiated cervical cancers.",
keywords = "Cell cycle, Cervical cancer, Cyclin-dependent kinase, Human papillomavirus, Immortalization, Retinoblastoma tumour suppressor, Transformation, p16",
author = "Y. Nakao and X. Yang and M. Yokoyama and A. Ferenczy and Shou-Ching Tang and Pater, {M. M.} and A. Pater",
year = "1997",
month = "1",
day = "1",
doi = "10.1038/bjc.1997.243",
language = "English (US)",
volume = "75",
pages = "1410--1416",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "10",

}

TY - JOUR

T1 - Induction of p16 during immortalization by HPV 16 and 18 and not during malignant transformation

AU - Nakao, Y.

AU - Yang, X.

AU - Yokoyama, M.

AU - Ferenczy, A.

AU - Tang, Shou-Ching

AU - Pater, M. M.

AU - Pater, A.

PY - 1997/1/1

Y1 - 1997/1/1

N2 - The p16 (MTS1) tumour-suppressor gene is a cyclin-dependent kinase (cdk) inhibitor that decelerates the cell cycle by inactivating the cdks that phosphorylate the retinoblastoma tumour-suppressor gene (Rb) protein (pRb). In cervical cancers, pRb is inactivated by the HPV E7 oncoprotein or by mutations. The hypothesis of earlier reports was that the disruption of the p16/cdk-cyclin/Rb cascade is essential for malignant cervical transformation/carcinogenesis. We previously established in vitro model systems of cervical cancer representing four steps of oncogenic progression initiated by the two most common oncogenic HPVs in ectocervical and endocervical epithelial cells. This report used these systems to investigate the role of p16 in cervical cancers. A dramatic enhancement of the p16 RNA level was observed after immortalization by HPV 16 or 18. Furthermore, the p16 protein was newly observed following immortalization. However, no further changes were found for RNA or protein levels after serum selection or malignant transformation. For three cervical carcinoma cell lines, similar high levels of p16 expression were seen. Point mutations or homozygous deletions of p16 were not observed in the in vitro systems or in clinical specimens. These results suggest that the inactivation of the p16/cdk-cyclin/Rb cascade does not occur during malignant transformation but occurs during the immortalization by HPV in HPV-harbouring premalignant lesions, the in situ equivalent of immortalized cells. Also suggested is that p16 has no role in the specific malignant transformation step from immortal premalignant lesions during the carcinogenesis of HPV-initiated cervical cancers.

AB - The p16 (MTS1) tumour-suppressor gene is a cyclin-dependent kinase (cdk) inhibitor that decelerates the cell cycle by inactivating the cdks that phosphorylate the retinoblastoma tumour-suppressor gene (Rb) protein (pRb). In cervical cancers, pRb is inactivated by the HPV E7 oncoprotein or by mutations. The hypothesis of earlier reports was that the disruption of the p16/cdk-cyclin/Rb cascade is essential for malignant cervical transformation/carcinogenesis. We previously established in vitro model systems of cervical cancer representing four steps of oncogenic progression initiated by the two most common oncogenic HPVs in ectocervical and endocervical epithelial cells. This report used these systems to investigate the role of p16 in cervical cancers. A dramatic enhancement of the p16 RNA level was observed after immortalization by HPV 16 or 18. Furthermore, the p16 protein was newly observed following immortalization. However, no further changes were found for RNA or protein levels after serum selection or malignant transformation. For three cervical carcinoma cell lines, similar high levels of p16 expression were seen. Point mutations or homozygous deletions of p16 were not observed in the in vitro systems or in clinical specimens. These results suggest that the inactivation of the p16/cdk-cyclin/Rb cascade does not occur during malignant transformation but occurs during the immortalization by HPV in HPV-harbouring premalignant lesions, the in situ equivalent of immortalized cells. Also suggested is that p16 has no role in the specific malignant transformation step from immortal premalignant lesions during the carcinogenesis of HPV-initiated cervical cancers.

KW - Cell cycle

KW - Cervical cancer

KW - Cyclin-dependent kinase

KW - Human papillomavirus

KW - Immortalization

KW - Retinoblastoma tumour suppressor

KW - Transformation

KW - p16

UR - http://www.scopus.com/inward/record.url?scp=0030960749&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030960749&partnerID=8YFLogxK

U2 - 10.1038/bjc.1997.243

DO - 10.1038/bjc.1997.243

M3 - Article

VL - 75

SP - 1410

EP - 1416

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 10

ER -